BOIRON Logo

BOIRON

ISIN

FR0000061129

Ticker

BOI

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

France

Year Founded

1932

About BOIRON

Company Description

Boiron is an independent, family-owned pharmaceutical laboratory specialising in the manufacture of very high quality homeopathic medicines. Present in more than 50 countries (20 subsidiaries), and with more than 2,700 employees, we develop our health project with rigour and passion. For Laboratoires Boiron, health is much more than a business, it is our mission. This is why we produce, in France, effective, risk-free, high-quality health products thanks to our unique pharmaceutical expertise in homeopathy.

We are committed to patients and all health professionals to contribute to a more human, respectful and sustainable medicine.

Our corporate philosophy has always been based on a sincere and shared commitment to improving health, fostering human relations, increasing well-being at work and actively contributing to the protection of our planet.

Headcount

2,700

Served Area

Worldwide

Headquarters

2 Avenue de l'Ouest Lyonnais
69510, Messimy
France

Financial statements

Download as Excel
Line item in (eur) 01.01.2021 01.01.2022 01.01.2023
Assets N/A 770,700,000.00 789,493,000.00
Noncurrent Assets N/A 318,336,000.00 311,660,000.00
Property Plant And Equipment N/A 162,793,000.00 152,491,000.00
Goodwill N/A 89,635,000.00 94,002,000.00
Intangible Assets Other Than Goodwill N/A 30,993,000.00 31,887,000.00
Deferred Tax Assets N/A 21,894,000.00 19,130,000.00
Other Noncurrent Assets N/A 41,000.00 39,000.00
Current Assets N/A 452,364,000.00 477,833,000.00
Inventories N/A 85,556,000.00 96,924,000.00
Trade And Other Current Receivables N/A 97,340,000.00 100,536,000.00
Current Tax Assets Current N/A 2,783,000.00 1,394,000.00
Cash and cash equivalents N/A 234,504,000.00 250,945,000.00
Noncurrent Assets Or Disposal Groups Classified As Held For Sale N/A 2,384,000.00 1,693,000.00
Other Current Assets N/A 29,797,000.00 26,341,000.00
Equity And Liabilities N/A 770,700,000.00 789,493,000.00
Equity 513,531,000.00 531,771,000.00 557,346,000.00
Issued Capital N/A 17,545,000.00 17,545,000.00
Share Premium N/A 79,876,000.00 79,876,000.00
Equity Attributable To Owners Of Parent N/A 531,735,000.00 557,616,000.00
Noncontrolling Interests N/A 36,000.00 -270,000.00
Noncurrent Liabilities N/A 80,691,000.00 78,960,000.00
Noncurrent Provisions For Employee Benefits N/A 71,557,000.00 60,759,000.00
Other Longterm Provisions N/A 143,000.00 143,000.00
Deferred Tax Liabilities N/A N/A 0.00
Other Noncurrent Liabilities N/A 1,272,000.00 1,320,000.00
Longterm Borrowings N/A 2,347,000.00 11,564,000.00
Current Liabilities N/A 158,238,000.00 153,187,000.00
Current Provisions N/A 49,884,000.00 29,389,000.00
Trade And Other Current Payables To Trade Suppliers N/A 44,180,000.00 48,250,000.00
Current Tax Liabilities Current N/A 1,328,000.00 2,113,000.00
Other Current Liabilities N/A 57,959,000.00 68,007,000.00
Line item in (eur) 01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 455,201,000.00 N/A
Interest Income On Cash And Cash Equivalents 590,000.00 1,817,000.00
Revenue From Contracts With Customers 455,201,000.00 534,239,000.00
Other Income 1,000.00 1,000.00
Profit Loss From Operating Activities 46,842,000.00 63,448,000.00
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method N/A 0.00
Profit Loss Before Tax 46,113,000.00 59,199,000.00
Income Tax Expense Continuing Operations 17,554,000.00 14,919,000.00
Profit (loss) 28,559,000.00 44,280,000.00
Profit Loss Attributable To Owners Of Parent 28,556,000.00 44,673,000.00
Profit Loss Attributable To Noncontrolling Interests 3,000.00 -393,000.00
Line item in (eur) 01.01.2022 01.01.2023
Profit (loss) 28,559,000.00 44,280,000.00
Adjustments For Decrease Increase In Inventories 1,255,000.00 -9,801,000.00
Adjustments For Increase Decrease In Trade Account Payable 4,941,000.00 -959,000.00
Other Adjustments To Reconcile Profit Loss -8,364,000.00 -10,426,000.00
Income Taxes Paid Refund Classified As Operating Activities 4,304,000.00 12,441,000.00
Cash Flows From Used In Operating Activities 33,317,000.00 58,690,000.00
Cash Flows From Losing Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 0.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A 1,706,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 10,340,000.00 7,582,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 10,988,000.00 10,237,000.00
Proceeds From Sales Of Intangible Assets Classified As Investing Activities 10,000.00 0.00
Purchase Of Intangible Assets Classified As Investing Activities 9,430,000.00 8,354,000.00
Cash Flows From Used In Investing Activities -11,921,000.00 -15,277,000.00
Payments To Acquire Or Redeem Entitys Shares N/A 6,079,000.00
Proceeds From Borrowings Classified As Financing Activities 3,000.00 22,000.00
Repayments Of Borrowings Classified As Financing Activities 1,171,000.00 963,000.00
Payments Of Lease Liabilities Classified As Financing Activities 4,401,000.00 4,623,000.00
Interest Paid Classified As Financing Activities 28,000.00 53,000.00
Cash Flows From Used In Financing Activities -21,995,000.00 -27,577,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes -599,000.00 15,836,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 368,000.00 -258,000.00
Cash and cash equivalents 234,504,000.00 250,945,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2021 - Q4 French 🇫🇷

Insider Trades

Date Trading entity / Person Association Trade type Volume
20.10.2023 None Other Sell EUR 34,037,282.40
20.10.2023 None Other Sell EUR 18,351,892.96
20.10.2023 None Other Sell EUR 10,789,373.76
20.10.2023 None Other Sell EUR 7,875,040.96
20.10.2023 None Other Sell EUR 233,876.00
20.10.2023 None Other Sell EUR 188,210.72
20.10.2023 None Other Sell EUR 118,047.92

Capital Markets Information

ISIN

FR0000061129

LEI

9695000UMPNY21KKDO98

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Euronext Paris

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.